Sermonix Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Series A3

  • Latest Deal Amount
  • $40M

  • Investors
  • 5

Sermonix Pharmaceuticals General Information

Description

Developer of pharmaceutical drugs intended to treat ESR1-mutated metastatic breast and gynecological cancers. The company's drugs are used for women's health, menopause, and selective estrogen receptor modulators, enabling cancer patients to get quality oncology products through proof of concept, clinical development, and regulatory approval.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 250 East Broad Street
  • Suite 250
  • Columbus, OH 43215
  • United States
+1 (614)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 250 East Broad Street
  • Suite 250
  • Columbus, OH 43215
  • United States
+1 (614)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sermonix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A3) 15-Nov-2021 $40M Completed Generating Revenue
3. Later Stage VC (Series A1) 31-Jul-2019 Completed Clinical Trials - Phase 2
2. Seed Round 28-Nov-2017 $4.2M $7.9M Completed Clinical Trials - Phase 2
1. Seed Round 10-Nov-2016 $3.7M $3.7M Completed Clinical Trials - Phase 2
To view Sermonix Pharmaceuticals’s complete valuation and funding history, request access »

Sermonix Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A3
Series A-2
Series A-1 1,998,257 $0.000100 5% $13.38 $13.38 1x $13.38 35.92%
To view Sermonix Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Sermonix Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical drugs intended to treat ESR1-mutated metastatic breast and gynecological cancers. The compan
Drug Discovery
Columbus, OH
11 As of 2025

San Diego, CA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sermonix Pharmaceuticals Competitors (75)

One of Sermonix Pharmaceuticals’s 75 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crinetics Pharmaceuticals Formerly VC-backed San Diego, CA
Genentech Formerly VC-backed South San Francisco, CA
Gilead Formerly VC-backed Foster City, CA
Altimmune Formerly VC-backed Gaithersburg, MD
Rein Therapeutics Formerly VC-backed Austin, TX
You’re viewing 5 of 75 competitors. Get the full list »

Sermonix Pharmaceuticals Patents

Sermonix Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026095931-A1 Neoadjuvant treatment of er+ breast cancer with lasofoxifene Pending 30-Oct-2024
WO-2026096820-A1 Neoadjuvant treatment of er+ breast cancer with lasofoxifene Pending 30-Oct-2024
AU-2025216603-A1 Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations Pending 30-Jan-2024
WO-2025165887-A1 Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations Pending 30-Jan-2024
WO-2025075631-A1 Lasofoxifene treatment of endocrine therapy resistant er+ cancer Inactive 06-Oct-2023 A61K31/40
To view Sermonix Pharmaceuticals’s complete patent history, request access »

Sermonix Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sermonix Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Xontogeny Accelerator/Incubator Minority
Angel (individual) Minority
Wild Family Office Family Office Minority
Angel (individual) Minority
Angel (individual) Minority
To view Sermonix Pharmaceuticals’s complete investors history, request access »

Sermonix Pharmaceuticals FAQs

  • When was Sermonix Pharmaceuticals founded?

    Sermonix Pharmaceuticals was founded in 2014.

  • Where is Sermonix Pharmaceuticals headquartered?

    Sermonix Pharmaceuticals is headquartered in Columbus, OH.

  • What is the size of Sermonix Pharmaceuticals?

    Sermonix Pharmaceuticals has 11 total employees.

  • What industry is Sermonix Pharmaceuticals in?

    Sermonix Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Sermonix Pharmaceuticals a private or public company?

    Sermonix Pharmaceuticals is a Private company.

  • What is the current valuation of Sermonix Pharmaceuticals?

    The current valuation of Sermonix Pharmaceuticals is .

  • What is Sermonix Pharmaceuticals’s current revenue?

    The current revenue for Sermonix Pharmaceuticals is .

  • How much funding has Sermonix Pharmaceuticals raised over time?

    Sermonix Pharmaceuticals has raised $73.9M.

  • Who are Sermonix Pharmaceuticals’s investors?

    Xontogeny, , Wild Family Office, , and have invested in Sermonix Pharmaceuticals.

  • Who are Sermonix Pharmaceuticals’s competitors?

    Crinetics Pharmaceuticals, Genentech, Gilead, Altimmune, and Rein Therapeutics are some of the 75 competitors of Sermonix Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process